Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERMAX vs CYCLOSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Parkinson's disease,Hyperprolactinemia
FDA-approved: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,Off-label: Parkinson's disease, hyperprolactinemia, acromegaly, neuroleptic malignant syndrome.
Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Terminal elimination half-life: 27 hours (range 24-30 hours) in healthy adults; significantly prolonged in renal impairment (up to 100+ hours in ESRD), requiring dose adjustment.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Hepatic (CYP3A4, CYP1A2); extensive first-pass metabolism.
Primarily hepatic via cytochrome P450 3A4 (CYP3A4). Inactive metabolites are excreted mainly in feces (80%) and urine (2-10% unchanged).
Renal: ~50% unchanged drug; biliary/fecal: ~40% as metabolites and parent drug; total clearance approximates hepatic blood flow.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
~90% bound to plasma proteins (primarily albumin).
~20–30% bound, primarily to albumin.
Vd: 6-8 L/kg (central compartment ~0.5 L/kg), indicating extensive tissue distribution.
0.5–1.0 L/kg, indicating moderate distribution into tissues.
Oral: ~50% (range 30-70%) due to first-pass hepatic metabolism; food does not significantly affect absorption.
Oral: ~65–75% due to first-pass metabolism.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated in patients with e GFR <30 m L/min/1.73 m2. For e GFR 30-50 m L/min/1.73 m2: maximum dose 0.8 mg daily.
Child-Pugh Class A: use with caution, consider dose reduction; Child-Pugh Class B or C: contraindicated.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Safety and efficacy not established; no approved pediatric dosing.
Not approved for pediatric patients. Safety and efficacy in patients <18 years have not been established.
Start at low end of dosing range (0.05 mg once daily); titrate slowly due to increased risk of hypotension and hallucinations.
Start at 0.8 mg once daily; titrate slowly due to increased risk of orthostatic hypotension and hypoglycemia. Consider renal function and comorbidities.
None.
None.
May cause valvular heart disease; fibrotic complications (pleural, pericardial, peritoneal); sudden sleep onset; orthostatic hypotension; hallucinations; impulse control disorders; dopamine agonist withdrawal syndrome.
Risk of hypotension, especially at initiation of therapy; monitor blood pressure.,May cause somnolence and dizziness; advise patients not to drive or operate machinery until effects are known.,Use with caution in patients with cardiovascular disease, especially those with angina or recent myocardial infarction.,May exacerbate psychotic disorders; use caution in patients with a history of psychosis.,Fibrotic complications (pulmonary, pericardial, retroperitoneal fibrosis) have been reported with ergot-derived dopamine agonists; monitor for symptoms.,Discontinue if signs of cardiac valvulopathy occur.
Hypersensitivity to pergolide; ergot alkaloid allergy; history of cardiac valvulopathy.
Hypersensitivity to bromocriptine or any component of the formulation.,Concomitant use with CYP3A4 inducers (e.g., rifampin, anticonvulsants) or inhibitors (e.g., azole antifungals, macrolide antibiotics).,Severe ischemic heart disease or peripheral vascular disorders.,Syncopal migraine or history of myocardial infarction with residual arrhythmias.,Uncontrolled hypertension.,Lactation: inhibits lactation, do not use in women with pregnancy or nursing unless essential.
No specific food interactions documented. However, high-protein meals may reduce absorption; take consistently with or without food. Avoid alcohol due to additive CNS depression.
Avoid alcohol and alcohol-containing products. No specific food interactions; take with or without food. Maintain adequate hydration.
Pergolide (PERMAX) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but no adequate, well-controlled studies in pregnant women exist. First trimester: theoretical risk due to dopamine agonist activity; second/third trimester: limited data, risk of postpartum hemorrhage due to ergot alkaloid properties. Use only if benefit outweighs risk.
First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause maternal hypoglycemia which can affect fetus.
Pergolide suppresses lactation by inhibiting prolactin secretion. It is excreted in human breast milk; M/P ratio not established. Contraindicated in breastfeeding women due to potential for dopamine receptor stimulation in infant and suppression of lactation.
Not recommended; no data on excretion in human milk. M/P ratio unknown.
No specific dose adjustment guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce serum levels, but efficacy and safety data are lacking. Use lowest effective dose if unavoidable. Avoid postpartum due to lactation suppression effects.
Monitor glucose closely; dose adjustments may be needed due to altered pharmacokinetics in pregnancy (increased clearance). Start at lowest effective dose; titrate based on glycemic response.
Permax (pergolide) is a dopamine receptor agonist used for Parkinson's disease. Due to risk of valvular heart disease, it is withdrawn from the US market; use only in exceptional cases with echocardiogram monitoring. Titrate slowly to avoid orthostatic hypotension. May cause sudden sleep episodes; advise patients not to drive. Do not abruptly discontinue (risk of neuroleptic malignant syndrome).
Monitor for hypoglycemia, especially in elderly patients or those with renal impairment. Cycloserine may accumulate in renal insufficiency; dose reduction is necessary if Cr Cl < 50 m L/min. Watch for neuropsychiatric effects (seizures, psychosis, depression) and discontinue if severe. Pyridoxine 50-100 mg daily is recommended to reduce neurotoxicity. Avoid alcohol due to increased seizure risk.
Take exactly as prescribed; do not stop suddenly without consulting doctor.,May cause dizziness, especially when standing up; rise slowly and avoid sudden position changes.,Can cause sudden sleepiness; do not drive or operate machinery until you know how the drug affects you.,Report any new or worsening heart palpitations, shortness of breath, or swelling in ankles/feet.,Avoid alcohol as it may increase dizziness and drowsiness.
Take exactly as prescribed; do not miss doses or double up.,Report any signs of rash, confusion, dizziness, or unusual behavior immediately.,Avoid alcohol completely while on this medication.,If you have kidney problems, your dose may need adjustment.,Take pyridoxine (vitamin B6) as directed to lower risk of side effects.,Do not drive or operate heavy machinery if you feel drowsy or dizzy.,Complete the full course of therapy even if you feel better.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERMAX vs CYCLOSET, answered by our medical review team.
PERMAX is a Dopamine Agonist that works by Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.. CYCLOSET is a Dopamine Agonist / Antidiabetic that works by Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERMAX and CYCLOSET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERMAX is: Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.. The standard adult dose of CYCLOSET is: 1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERMAX and CYCLOSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERMAX is classified as Category C. Pergolide (PERMAX) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but no adequate, well-controlled studies in pregnant women ex. CYCLOSET is classified as Category C. First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.